GlassScriptPhysician profile
Sonali Biligiri
NPI 1245611805
$3,952.58
in general payments reported to CMS, 2019-2025
28 companies · none reported in 2025
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $35.59 · 2021: $2,741 · 2022: $1,159 · 2023: $16.12.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $16.12.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $16.12 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $743.10 | 2021-2022 | |
| Novo Nordisk INC | $703.83 | 2021-2022 | |
| Sanofi-Aventis U.S. LLC | $259.28 | 2021-2022 | |
| Daiichi Sankyo INC. | $242.54 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $234.01 | 2021-2022 | |
| Abbott Laboratories | $233.24 | 2021-2023 | Freestyle Libre 3 |
| Abbvie INC. | $227.09 | 2021-2022 | |
| Insulet Corporation | $165.92 | 2022 | |
| Lilly USA, LLC | $165.71 | 2020-2022 | |
| Dexcom, INC. | $132.84 | 2021 | |
| Corcept Therapeutics | $101.73 | 2021 | |
| Pfizer INC. | $97.78 | 2021-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $97.42 | 2022 | |
| Lifescan, INC. | $81.59 | 2021-2022 | |
| Sunovion Pharmaceuticals INC. | $72.37 | 2021 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kowa Pharmaceuticals America, INC. | $60.64 | 2020-2021 | |
| Recordati_rare_diseases_inc. | $55.17 | 2021 | |
| Amarin Pharma, INC. | $49.80 | 2021-2022 | |
| Ultragenyx Pharmaceutical INC. | $43.84 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $36.15 | 2021 | |
| Merck Sharp & Dohme LLC | $27.94 | 2021 | |
| Tandem Diabetes Care, INC. | $23.13 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $19.02 | 2022 | |
| Ibsa Pharma INC. | $18.90 | 2021 | |
| Esperion Therapeutics, INC. | $17.07 | 2021 | |
| Ipsen Biopharmaceuticals, INC | $16.30 | 2022 | |
| Medtronic, INC. | $14.91 | 2021 | |
| Xeris Pharmaceuticals, INC. | $11.26 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sonali Biligiri listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.